Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability

Codis, a global contract development and manufacturing organization (CDMO), has announced an agreement to acquire Catalent's Nottingham facility in the UK. The deal, which is expected to close in the third quarter of 2026, is set to enhance Codis' capabilities in spray drying and solid dose development. While the financial terms of the transaction have not been disclosed, the acquisition marks a significant step for Codis in solidifying its position as a leading provider of integrated spray dry solutions in Europe.

The Nottingham site, which has over two decades of experience in oral solid dose (OSD) development and small-scale manufacturing, will significantly bolster Codis' particle engineering expertise. This facility is known for its strong scientific capabilities in formulation development and clinical supply, having successfully delivered development-scale spray drying and OSD solutions. The addition of the Nottingham team is expected to create synergies with Codis' existing operations, particularly its commercial-scale facility in Haverhill, UK, which is currently undergoing expansion with a new GEA Pharma-SD® type PSD-4 commercial spray dryer.

Strategically, this acquisition aligns with Codis' goal to provide a comprehensive single partner path for integrated spray drying solutions, ranging from development through to clinical supply and commercial intermediates. By consolidating formulation development and good manufacturing practice (GMP) manufacturing within the same organization and quality system, Codis aims to mitigate one of the greatest risks in drug development: the transition from formulation to commercial-scale manufacturing. This integrated approach is particularly crucial given that many small-molecule drug candidates face challenges related to poor solubility, and spray-dried dispersions are increasingly recognized as a key method for enhancing bioavailability.

The broader market implications of this acquisition underscore a growing trend in the pharmaceutical sector towards consolidation among CDMOs. As companies seek to streamline their operations and enhance their service offerings, acquisitions like that of Codis and Catalent's Nottingham facility reflect the ongoing demand for integrated solutions in drug development and manufacturing. The strategic positioning of Codis, with its enhanced capabilities, is likely to attract more clients seeking comprehensive support in the increasingly competitive landscape of pharmaceutical development.

Overall, the acquisition is poised to strengthen Codis' market presence in Europe, enhancing its ability to deliver innovative solutions in particle engineering and solid dose development. As the pharmaceutical industry continues to evolve, Codis' expanded capabilities may provide a competitive edge, positioning the company favorably for future growth and partnership opportunities.